Filtered By:
Source: Stroke
Drug: Warfarin

This page shows you your search results in order of date. This is page number 2.

Order by Relevance | Date

Total 77 results found since Jan 2013.

Response by Bai et al to Letter Regarding Article, “Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation: Systematic Review and Meta-Analysis” Letter to the Editor
Source: Stroke - May 22, 2017 Category: Neurology Authors: Ying Bai, Alena Shantsila, Gregory Y.H. Lip Tags: Arrhythmias Letters to the Editor Source Type: research

Ischemic Stroke in Nonvalvular Atrial Fibrillation at Warfarin Initiation Clinical Sciences
Conclusions—Warfarin effect was qualitatively different in the first 30 days after initiation than subsequently. This is consistent with a modest increase in stroke risk occurring briefly after starting warfarin.
Source: Stroke - May 22, 2017 Category: Neurology Authors: Ping G. Tepper, Xianchen Liu, Melissa Hamilton, Jack Mardekian, William Petkun, Wilson Tan, Daniel E. Singer Tags: Epidemiology Original Contributions Source Type: research

Is There an Obesity Paradox for Outcomes in Atrial Fibrillation? Clinical Sciences
Conclusions—There may be an obesity paradox in atrial fibrillation patients, particularly for all-cause and cardiovascular death outcomes. An obesity paradox was also evident for stroke/systemic embolic event outcome in NOAC trials, with a treatment effect favoring NOACs over warfarin for both efficacy and safety that was significant only for normal weight patients.
Source: Stroke - March 27, 2017 Category: Neurology Authors: Marco Proietti, Elisa Guiducci, Paola Cheli, Gregory Y.H. Lip Tags: Catheter Ablation and Implantable Cardioverter-Defibrillator, Obesity, Anticoagulants, Quality and Outcomes Original Contributions Source Type: research

Rivaroxaban Versus Dabigatran or Warfarin in Real-World Studies of Stroke Prevention in Atrial Fibrillation Clinical Sciences
Conclusions—In this systematic review and meta-analysis, rivaroxaban was as effective as dabigatran, but was more effective than warfarin for the prevention of stroke/thromboembolism in atrial fibrillation patients. Major bleeding risk was significantly higher with rivaroxaban than with dabigatran, as was all-cause mortality and gastrointestinal bleeding. Rivaroxaban was comparable to warfarin for major bleeding, with an increased risk in gastrointestinal bleeding and decreased risk of intracranial hemorrhage.
Source: Stroke - March 27, 2017 Category: Neurology Authors: Ying Bai, Hai Deng, Alena Shantsila, Gregory Y.H. Lip Tags: Meta Analysis, Quality and Outcomes Original Contributions Source Type: research

12/15-Lipoxygenase Inhibition or Knockout Reduces Warfarin-Associated Hemorrhagic Transformation After Experimental Stroke Basic Sciences
Conclusions—In addition to its benefits in infarct size reduction, 12/15-LOX inhibition also may independently reduce HT in warfarin-treated mice. ML351 should be further evaluated as stroke treatment in anticoagulated patients suffering a stroke, either alone or in conjunction with tissue-type plasminogen activator.
Source: Stroke - January 22, 2017 Category: Neurology Authors: Yu Liu, Yi Zheng, Hulya Karatas, Xiaoying Wang, Christian Foerch, Eng H. Lo, Klaus van Leyen Tags: Blood-Brain Barrier, Ischemic Stroke, Neuroprotectants Original Contributions Source Type: research

Anticoagulation Use and Clinical Outcomes After Major Bleeding on Dabigatran or Warfarin in Atrial Fibrillation Clinical Sciences
Conclusions—Dabigatran was associated with a superior benefit/risk ratio than warfarin and anticoagulation discontinuation in the treatment of atrial fibrillation patients who have survived a major bleed.
Source: Stroke - December 22, 2016 Category: Neurology Authors: Inmaculada Hernandez, Yuting Zhang, Maria M. Brooks, Paul K.L. Chin, Samir Saba Tags: Atrial Fibrillation, Quality and Outcomes, Intracranial Hemorrhage, Ischemic Stroke Original Contributions Source Type: research

Letter by Chen et al Regarding Article, “Left Ventricular Eȷection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Eȷection Fraction Trial” Letter to the Editor
Source: Stroke - November 27, 2016 Category: Neurology Authors: Chen Chen, Dongze Li, Lixia Deng Tags: Arrhythmias, Heart Failure, Complications, Cerebrovascular Disease/Stroke Letters to the Editor Source Type: research

Response by Di Tullio et al to Letter Regarding Article, “Left Ventricular Eȷection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Eȷection Fraction Trial” Letter to the Editor
Source: Stroke - November 27, 2016 Category: Neurology Authors: Marco R. Di Tullio, John L.P. Thompson, Shunichi Homma, for the WARCEF Investigators Tags: Heart Failure, Cerebrovascular Disease/Stroke Letters to the Editor Source Type: research

Renal Function and the Risk of Stroke and Bleeding in Patients With Atrial Fibrillation Clinical Sciences
Background and Purpose—We sought to determine the risk of stroke/thromboembolism and bleeding associated with reduced renal function in patients with atrial fibrillation and the risk of stroke and bleeding associated with warfarin treatment in specific estimated glomerular filtration rate (eGFR) groups.Methods—We conducted a register-based cohort study and included patients discharged with nonvalvular atrial fibrillation from 1997 to 2011 with available eGFR.Results—A total of 17 349 patients were identified with eGFR available at baseline. All levels of lower eGFR were associated with higher risk of stroke/thrombo...
Source: Stroke - October 23, 2016 Category: Neurology Authors: Bonde, A. N., Lip, G. Y. H., Kamper, A.–L., Fosbol, E. L., Staerk, L., Carlson, N., Torp–Pedersen, C., Gislason, G., Olesen, J. B. Tags: Atrial Fibrillation Original Contributions Source Type: research

Validation of a Modified CHA2DS2-VASc Score for Stroke Risk Stratification in Asian Patients With Atrial Fibrillation: A Nationwide Cohort Study Clinical Sciences
Conclusions— In this Asian atrial fibrillation cohort, the mCHA2DS2-VASc score performed better than the CHA2DS2-VASc and would further identify atrial fibrillation patients who may derive a positive net clinical benefit from oral anticoagulation.
Source: Stroke - September 25, 2016 Category: Neurology Authors: Chao, T.-F., Lip, G. Y. H., Liu, C.-J., Tuan, T.-C., Chen, S.-J., Wang, K.-L., Lin, Y.-J., Chang, S.-L., Lo, L.-W., Hu, Y.-F., Chen, T.-J., Chiang, C.-E., Chen, S.-A. Tags: Atrial Fibrillation Clinical Sciences Source Type: research

Noncontrast Computed Tomography Hypodensities Predict Poor Outcome in Intracerebral Hemorrhage Patients Clinical Sciences
Conclusions— The presence of noncontract CT hypodensities at baseline independently predicts poor outcome and comes as a useful and widely available addition to our ability to predict ICH patients’ clinical evolution.
Source: Stroke - September 25, 2016 Category: Neurology Authors: Boulouis, G., Morotti, A., Brouwers, H. B., Charidimou, A., Jessel, M. J., Auriel, E., Pontes-Neto, O., Ayres, A., Vashkevich, A., Schwab, K. M., Rosand, J., Viswanathan, A., Gurol, M. E., Greenberg, S. M., Goldstein, J. N. Tags: Computerized Tomography (CT), Prognosis, Mortality/Survival, Cerebrovascular Disease/Stroke, Intracranial Hemorrhage Clinical Sciences Source Type: research

Left Ventricular Ejection Fraction and Risk of Stroke and Cardiac Events in Heart Failure: Data From the Warfarin Versus Aspirin in Reduced Ejection Fraction Trial Clinical Sciences
Conclusions— In patients with systolic HF and sinus rhythm, LVEF is inversely associated with death and its components, whereas an association with stroke exists for very low LVEF values. An interaction with warfarin treatment on stroke risk may exist. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00041938.
Source: Stroke - July 24, 2016 Category: Neurology Authors: Di Tullio, M. R., Qian, M., Thompson, J. L. P., Labovitz, A. J., Mann, D. L., Sacco, R. L., Pullicino, P. M., Freudenberger, R. S., Teerlink, J. R., Graham, S., Lip, G. Y. H., Levin, B., Mohr, J. P., Buchsbaum, R., Estol, C. J., Lok, D. J., Ponikowski, P. Tags: Heart Failure, Echocardiography, Anticoagulants, Ischemic Stroke Clinical Sciences Source Type: research

Outcomes With Edoxaban Versus Warfarin in Patients With Previous Cerebrovascular Events: Findings From ENGAGE AF-TIMI 48 (Effective Anticoagulation With Factor Xa Next Generation in Atrial Fibrillation-Thrombolysis in Myocardial Infarction 48) Clinical Sciences
Conclusions— Patients with atrial fibrillation with previous IS/TIA are at high risk of recurrent thromboembolism and bleeding. HDER is at least as effective and is safer than warfarin, regardless of the presence or the absence of previous IS or TIA. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00781391.
Source: Stroke - July 24, 2016 Category: Neurology Authors: Rost, N. S., Giugliano, R. P., Ruff, C. T., Murphy, S. A., Crompton, A. E., Norden, A. D., Silverman, S., Singhal, A. B., Nicolau, J. C., SomaRaju, B., Mercuri, M. F., Antman, E. M., Braunwald, E., on behalf of the ENGAGE AF-TIMI 48 Investigators Tags: Atrial Fibrillation, Anticoagulants, Ischemic Stroke Clinical Sciences Source Type: research

Risk Profile of Symptomatic Lacunar Stroke Versus Nonlobar Intracerebral Hemorrhage Brief Reports
Conclusions— The risk factor profile of dICH differs from that associated with LS. This might be used for disease risk stratification at individual level.
Source: Stroke - July 24, 2016 Category: Neurology Authors: Morotti, A., Paciaroni, M., Zini, A., Silvestrelli, G., Del Zotto, E., Caso, V., DellAcqua, M. L., Simone, A. M., Lanari, A., Costa, P., Poli, L., De Giuli, V., Gamba, M., Ciccone, A., Ritelli, M., Di Castelnuovo, A., Iacoviello, L., Colombi, M., Agnelli, Tags: Intracranial Hemorrhage, Ischemic Stroke Brief Reports Source Type: research

Cost-Effectiveness of Oral Anticoagulants for Ischemic Stroke Prophylaxis Among Nonvalvular Atrial Fibrillation Patients Clinical Sciences
Conclusions— All the newer oral anticoagulants compared were more effective than adjusted dosed warfarin. Our model showed that apixaban was the most effective anticoagulant in a general atrial fibrillation population and has an incremental cost-effectiveness ratio <$50 000/QALY. For those with higher stroke risk (CHADS2≥3), dabigatran was the most cost-effective treatment option.
Source: Stroke - May 22, 2016 Category: Neurology Authors: Shah, A., Shewale, A., Hayes, C. J., Martin, B. C. Tags: Anticoagulants, Cost-Effectiveness, Ischemic Stroke Clinical Sciences Source Type: research